Biotech China 2014

Cancer Biology: Princess Margaret Hospital

Total Score People Score Events Score
48 37 17
Date Event Presentation Speakers
March 5, 2014 Targeted Anticancer Therapies Methodological and Organizational Issues in Drug dDvelopment of Targeted Agents Lillian L. Siu
October 27, 2013 Nature - CNIO Cancer Symposium: Frontiers in Tumour Heterogeneity and Plasticity The Development of Predictive Biomarkers in Clinical Trials in the Context of Potential Tumor Heterogeneity Lillian L. Siu
July 6, 2011 3rd WIN Symposium Pharmacogenomic testing - matching patients with targeted drugs Lillian L. Siu
March 6, 2011 Stem Cells, Cancer and Metastasis (C4) Regulation of the Mammary Stem Cell Niche Rama Khokha
February 17, 2011 15th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma Highlights in the Management of Transplantation-Eligible Patients With Newly Diagnosed Myeloma Donna Reece
Multiple Myeloma Donna Reece
September 3, 2010 Fourth Asian Pacific Conference: Perspectives in Lung Cancer Clinical trial on molecular targeting agent: What is right and what is wrong? Frances Shepherd
August 10, 2010 The International Quantitative Imaging Cytometry Centers of Excellence Provide a Forum for Educational and Training Programs in Quantitative Imaging Cytometry, with a Specific Focus on Solid-Phase Laser Scanning Imaging Cytometry Application of Imaging Cytometry to the Molecular Therapeutics of Human Solid Tumors David W. Hedley
August 6, 2010 Australian-Canadian Prostate Cancer Research Alliance Symposium Central Room A | Session topic: The Tumour Microenvironment Dr Robert Bristow
October 1, 2009 6TH ANNUAL MEETING OF THE INTERNATIONAL SOCIETY OF GASTROINTESTINAL ONCOLOGY (ISGIO) Metastatic Pancreatic Cancer: How to Select the Best Options Malcolm J Moore
December 7, 2008 AMERICAN SOCIETY FOR MATRIX BIOLOGY 2008 Meeting Concurrent G: TIMPs and Tissue Homeostasis Rama Khokha
November 4, 2008 The Chemotherapy Foundation Symposium XXVI OR Chemotherapy Foundation Symposium, Innovative Cancer Therapy for Tomorrow DEALING WITH EMOTIONS, STRENGTHENING RELATIONSHIPS Robert A. , Buckman
May 30, 2008 44th ASCO Annual Meeting Program Committee Juanita Crook
May 30, 2008 ASCO Annual'08 Meeting cancer prevention/epidemiology-- How to Interpret and Communicate the Risks of Therapy-Related Complications: Demystifying Epidemiologic Research (M08) Mary K. Gospodarowicz
lymphoma and plasma cell disorders-- How to Interpret and Communicate the Risks of Therapy-Related Complications: Demystifying Epidemiologic Research (M08) Mary K. Gospodarowicz
patient and survivor care-- How to Interpret and Communicate the Risks of Therapy-Related Complications: Demystifying Epidemiologic Research (M08) Mary K. Gospodarowicz
meet the professor sessions-- How to Interpret and Communicate the Risks of Therapy-Related Complications: Demystifying Epidemiologic Research (M08) Mary K. Gospodarowicz
January 18, 2008 Translational Research Program Stem Cell Symposium Critique/Discussion Robert G Bristow
November 29, 2007 Cell Signalling and Novel Cancer Therapeutics EGFR antagonists - response in the clinic Frances Shepherd
November 15, 2007 The Joint Meeting of the 4th ISC International Conference on Cancer Therapeutics and The 7th Princess Margaret Hospital Conference: New Developments in Cancer Management Welcome from PMH Mary K. Gospodarowicz
Welcome from ISC Ronald Feld
Predictive biomarkers in targeted therapy: Lessons learned Ming-Sound Tsao
Session I: Targeted Therapies I Ming-Sound Tsao
Going beneath the surface: Novel agents for downstream signaling targets David W. Hedley
Targeted therapies for CNS malignancies Warren P. Mason
Surgical debate: Is there a role for surgery in stage IIIA NSCLC? Gail E. Darling
Session III: Gastrointestinal malignancies Eric X. Chen
Targeted therapy of pancreas Malcolm J Moore
Liver radiotherapy Laura A. Dawson
Welcome to day two Ronald Feld
PET/CT for GI tumors Ur Metser
Session V: Genitourinary Neil Fleshner, Srikala Sridhar
Image guided therapy in prostate cancer John Trachtenberg
Targeted radiotherapy in urologic cancer Cynthia Ménard
Session VI: Targeted Therapies II Mary K. Gospodarowicz
Measuring residual DNA damage in situ as a clinical biomarker of molecular target inhibition in radiotherapy and chemotherapy trials Robert G Bristow
Challenges in the design of early phase clinical trials evaluating combinations of radiotherapy and molecularly targeted therapies Anthony Brade
Session VII: Malignant Hematology Michael Crump, Hans A. Messner
Update on chelation therapy Karen W.L. Yee
Management of patients with CML: Beyond imatinib Jeffrey H. Lipton
Management of the elderly with acute myeloid leukemia Joseph Brandwein
Targeted therapy for lymphoma Michael Crump
Targeted therapy in the elderly Lillian L. Siu
Welcome to day three Ronald Feld
Pharmacogenomic markers in lung cancer Geoffrey Liu
Session X: Breast Cancer Natasha Leighl, David Warr
Targeted therapy: Targeting tumors or targeting patients? Christine Simmons
Session XI: Supportive Care: Managing Toxicities of Targeted Agents Janice Wright
Safety and efficacy of rituximab abbreviated infusion Tracy Nagy
Session XII: Challenging Cases Ronald Feld, Joseph Mikhael
Bladder cancer: Adjuvant versus neoadjuvant therapies Srikala Sridhar
Lymphoma: Maintenance therapy Vishal Kukreti
Locally advanced lung cancer: Combined modality therapy Andrea Bezjak, Natasha Leighl
October 15, 2007 2nd Annual Innovations in Clinical Trials: Implementations of Biomarkers (Oct15-16) CASE STUDIES: Biomarker Development from Validation to Clinical Implementation (13:25-14:10) Geoffrey Liu, Ming-Sound Tsao
CASE STUDIES - Predictive Biomarkers for Response to EGFR Therapy - Validation Perspective: (13:30-13:50) Ming-Sound Tsao
CASE STUDIES - Predictive Biomarkers for Response to EGFR Therapy - Clinical Perspective: (13:30-13:50) Geoffrey Liu
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.